Chemoselective, Scalable Nickel‐Electrocatalytic
<i>O</i>
‐Arylation of Alcohols
作者:Hai‐Jun Zhang、Longrui Chen、Martins S. Oderinde、Jacob T. Edwards、Yu Kawamata、Phil S. Baran
DOI:10.1002/anie.202107820
日期:2021.9.13
The formation of aryl-alkyl ether bonds through cross coupling of alcohols with aryl halides represents a useful strategic departure from classical SN2 methods. Numerous tactics relying on Pd-, Cu-, and Ni-based catalytic systems have emerged over the past several years. Herein we disclose a Ni-catalyzed electrochemically driven protocol to achieve this useful transformation with a broad substrate
通过醇与芳基卤的交叉偶联形成芳基-烷基醚键代表了对经典S N 2 方法的有用的战略偏离。过去几年出现了许多依赖钯基、铜基和镍基催化系统的策略。在此,我们公开了一种镍催化电化学驱动方案,以一种操作简单的方式在广泛的底物范围内实现这种有用的转化。这种电化学方法不需要强碱、昂贵的外源过渡金属催化剂(例如铱、钌),并且可以轻松地在批量或流动设置中扩大规模。有趣的是,与机械相关的光化学变体相比,电子醚化表现出增强的底物范围,因为它耐受醇亲核试剂中的叔胺官能团。
PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF
申请人:MORITA Kohei
公开号:US20100093819A1
公开(公告)日:2010-04-15
A compound represented by the following general formula (1) or a salt thereof, which has superior inhibitory activity against type 4 PLA
2
, and thus has prostaglandin and/or leucotriene production suppressing action [X represents a halogen atom, an alkyl group which may be substituted, or the like, Y represents hydrogen atom or an alkyl group which may be substituted, and Z represents hydrogen atom or an alkyl group which may be substituted].
The present invention relates to compounds that are selective and/or potent inhibitors of UPPS. In addition to compounds which inhibit UPPS, the invention also provides pharmaceutical compositions comprising these compounds and methods of using these compounds for treating bacterial disease, such as bacterial infection.
selective formation of the corresponding benzamide and nitrogen oxides (mainly NO2−) in high yield. A similar oxidative cleavage of the CNOH bond of N-hydroxy-arylguanidines also occurs upon reaction with KO2; the yield of the corresponding urea is lower and large amounts of the corresponding cyanamide are also formed. The significance of this reaction of O2•− with compounds containing a CNOH bond in the
Management of ophthalmologic disorders, including macular degeneration
申请人:Rando R. Robert
公开号:US20060069078A1
公开(公告)日:2006-03-30
A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inihibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.